Avalon Pharma Secured Tirzepatide Licensing Deal
The pharmaceutical company acquired exclusive rights to market the diabetes medication across Saudi Arabia and the MENA region.
Updated on Oct. 11, 2026 in Diabetes
Live Poll
Does expanding local access to generic versions of high-cost medications improve healthcare in your community?
Avalon Pharma has entered into a licensing agreement with OneSource Specialty Pharma to register and commercialize Tirzepatide. The deal grants the firm exclusive rights to distribute the medication across the MENA region and Saudi Arabia.
Why it matters
The partnership expands Avalon Pharma's GLP-1 portfolio for diabetes and metabolic diseases while supporting the health objectives of Saudi Arabia's Vision 2030. It provides the company with long-term access to a key therapeutic drug.
The license covers six Tirzepatide dosage strengths ranging from 2.5 mg to 15 mg. The agreement carries an initial 10-year duration with provisions for automatic annual renewals.
The players
Avalon Pharma
A pharmaceutical company that acts as the marketing authorization holder for the new drug agreement.
OneSource Specialty Pharma
An India-based pharmaceutical entity that signed the licensing contract with Avalon Pharma.
The details
Avalon Pharma gains access to OneSource's regulatory dossier and the right to request a transfer of manufacturing technology following the product's commercial launch. The company will serve as the marketing authorization holder for the drug throughout the specified territories.
Timeline
October 8, 2026: The license agreement was signed.
December 31, 2025: The financial year end used for calculating the contract value.
Health Landscape
The agreement supports Saudi Arabia's Vision 2030 by bolstering the local availability of treatments for metabolic diseases. This move aligns with broader regional efforts to expand domestic portfolios of advanced GLP-1 therapies.
The agreement establishes a pathway for patients in the region to eventually access a wider variety of GLP-1 dosage options for diabetes management. Availability remains contingent upon the upcoming patent expiration timeline.
The takeaway
This licensing deal highlights the strategic importance of securing exclusive regional rights for high-demand metabolic drugs before patent cliffs occur. Companies are increasingly prioritizing these long-term agreements to ensure they can meet local demand for chronic disease treatments.
Further reading
For more background on current treatment trends, visit the Diabetes section.
Source note: This article includes information reported by Mubasher.
Live Poll
Does expanding local access to generic versions of high-cost medications improve healthcare in your community?
